Table 1:

Clinical characteristics of the cohort

		N
Age at diagnosis ( years)		88
Mean +/− SD	52 +/− 17
Median	54
Range	18–86
Presence of Distant metastasis at cancer diagnosis	47%
Age at distant metastasis diagnosis
Mean +/− SD	56 +/− 16
Median	59
Range	20–90
Gender
Female	52%	46
Histology
Papillary other than FV-PTC	43%	38
Follicular and FV-PTC	10%	9
Hurthle Cell	9%	8
Poorly Differentiated	38%	33
Size of primary tumor (cm)(if known)		141
Mean +/− SD	3.9 +/− 2.8
Median	3.4
Range	0.7–16
Thyroid Cancer stage at diagnosis		84
I	20%	17
II	11%	9
III	11%	9
IV	58%	49
Extrathyroidal extension (ETE)		63
None	32%	20
Minimal	43%	27
Gross	25%	16
Vascular invasion (VI)		61
None	20%	12
Present	80%	49
Initial Thyroid Surgery		88
Total	93%	82
Subtotal/Hemithyroidectomy	7%	6
EBRT to Neck		88
Yes	17%	15
Local Recurrence before DM diagnosis in M0 pts		47
Yes	36%	17
RAI adjuvant therapy
	85%	75
RAI adjuvant therapy activity (mCi)		74
Mean +/− SD	161 +/− 85
Median	150
Range	29–493
RAI Avidity at time of DM diagnosis		88
RAI Avid ( RAIA)	52%	46
RAI Refractory ( RAIR)	48%	42
FDG-PET Avidity		66
FDG-PET (+)	46%	30
FDG-PET (−)	54%	36
Distant Metastasis Distribution at DM diagnosis
Lung only	78%	69
Lung and Bone	16%	14
Lung and Other( including Bone)	4%	4
Lung and Liver	2%	1
Lung Metastasis Size Category at DM diagnosis		88
Micro ( < 1cm)	72%	63
Macro (≥ 1cm)	28%	25
Follow up since DM diagnosis ( years)
Mean +/− SD	9.1+/− 5.0
Median	8.5
Range	0.7–29.4
Clinical Outcome at End of Follow Up
Partial Response/Stable Disease (PR/SD)	15%	13
Disease Progression (DP)	85%	75
Status at end of Follow up
Alive	44%	39
Dead	56%	49
Cause of Death		49
Thyroid Cancer	84%	41
Myelodysplastic Syndrome	6%	2
Unknown	10%	5